Stage III/IV unresectable melanoma – require systemic drug therapy

**Guidance:**
Recommendations and practice points

**Evidence:**
Evidence statements
Systematic review evidence summary

V600 BRAF wildtype

**Option:** Anti PD-1 monotherapy

**Option:** Nivolumab + ipilimumab

V600 BRAF mutation positive

**Option:** combined BRAF inhibitor + MEK inhibitor

**Option:** nivolumab + ipilimumab

**Option:** anti-PD-1 monotherapy

**Evidence:**
Evidence statements
Systematic review evidence summary

Note: patients with brain metastases require discussion at multidisciplinary meeting to consider therapy sequencing of drug (BRAF + MEK or Ipilimumab + nivolumab) and/or surgery or radiotherapy (Brain metastases section to be added).